143 related articles for article (PubMed ID: 8726839)
21. Elevated PIVKA-II is associated with early recurrence and poor prognosis in BCLC 0-A hepatocellular carcinomas.
Wang BL; Tan QW; Gao XH; Wu J; Guo W
Asian Pac J Cancer Prev; 2014; 15(16):6673-8. PubMed ID: 25169507
[TBL] [Abstract][Full Text] [Related]
22. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
Fujiyama S; Morishita T; Sagara K; Sato T; Motohara K; Matsuda I
Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma.
Deyashiki Y; Nishioka Y; Takahashi K; Kosaka Y; Suzuki K
Cancer; 1989 Dec; 64(12):2546-51. PubMed ID: 2555040
[TBL] [Abstract][Full Text] [Related]
24. NX-PVKA levels before and after hepatectomy of hepatocellular carcinoma as predictors of patient survival: a preliminary evaluation of an improved assay for PIVKA-II.
Nanashima A; Abo T; Taura N; Shibata H; Ichikawa T; Takagi K; Arai J; Oyama S; Nagayasu T
Anticancer Res; 2013 Jun; 33(6):2689-97. PubMed ID: 23749928
[TBL] [Abstract][Full Text] [Related]
25. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Yoon YJ; Han KH; Kim DY
Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065
[TBL] [Abstract][Full Text] [Related]
26. [Clinical evaluation of PIVKA-II as a marker of hepatocellular carcinoma].
Arima K; Kodama T; Suga M; Sakamoto H; Ohe Y; Yachi A
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3049-52. PubMed ID: 2476968
[TBL] [Abstract][Full Text] [Related]
27. A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma.
Sohn A; Kim H; Yu SJ; Yoon JH; Kim Y
Anal Bioanal Chem; 2017 Apr; 409(11):2829-2838. PubMed ID: 28168546
[TBL] [Abstract][Full Text] [Related]
28. Liver cell adenoma in a 26-year-old man.
Mamada Y; Onda M; Tajiri T; Akimaru K; Yoshida H; Taniai N; Mineta S; Hirakata A; Hirose Y
J Nippon Med Sch; 2001 Dec; 68(6):516-9. PubMed ID: 11744932
[TBL] [Abstract][Full Text] [Related]
29. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies.
Nakao A; Taniguchi K; Inoue S; Takeda S; Harada A; Nonami T; Watanabe K; Takagi H
Am J Gastroenterol; 1997 Jun; 92(6):1031-4. PubMed ID: 9177525
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of PIVKA-II After Living-donor Liver Transplantation for Hepatocellular Carcinoma.
Park MS; Lee KW; Kim H; Choi YR; Hong G; Yi NJ; Suh KS
Transplant Proc; 2017 Jun; 49(5):1109-1113. PubMed ID: 28583537
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.
Kang SH; Kim DY; Jeon SM; Ahn SH; Park JY; Kim SU; Kim JK; Lee KS; Chon CY; Han KH
Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):849-56. PubMed ID: 22495400
[TBL] [Abstract][Full Text] [Related]
33. [Complete necrosis of a giant tumor in liver by transcatheter arterial embolization and percutaneous transhepatic portal embolization before liver resection].
Ishida N; Ishigure K; Watanabe T; Fujioka A; Nakamura Y; Furuta T; Sasaki Y
Nihon Shokakibyo Gakkai Zasshi; 2008 Aug; 105(8):1226-33. PubMed ID: 18679000
[TBL] [Abstract][Full Text] [Related]
34. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
Lamerz R; Runge M; Stieber P; Meissner E
Anticancer Res; 1999; 19(4A):2489-93. PubMed ID: 10470180
[TBL] [Abstract][Full Text] [Related]
35. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
36. [Development of highly sensitive assay for detection of low serum level of PIVKA-II and its clinical usefulness].
Sakizono K; Oita T; Kuroda M; Kasakura S
Rinsho Byori; 1996 Sep; 44(9):871-6. PubMed ID: 8911073
[TBL] [Abstract][Full Text] [Related]
37. [Clinical evaluation of PIVKA-II in patients with hepatocellular carcinoma. Detection of PIVKA-II by EIA using anti-PIVKA-II monoclonal antibody].
Ohtani M; Ido K; Kawamoto C; Kimura K
Rinsho Byori; 1989 Apr; 37(4):405-9. PubMed ID: 2545953
[No Abstract] [Full Text] [Related]
38. Histological study of PIVKA-II expression in hepatocellular carcinoma and adenomatous hyperplasia.
Miskad UA; Yano Y; Nakaji M; Kishi S; Itoh H; Kim SR; Ku Y; Kuroda Y; Hayashi Y
Pathol Int; 2001 Dec; 51(12):916-22. PubMed ID: 11844063
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation of plasma PIVKA-II as a new marker for hepatocellular carcinoma].
Tada H; Kagawa K; Hikita H; Takeuchi T; Ohta Y; Fukui S; Shintani H; Deguchi T; Okanoue T; Takino T
Gan No Rinsho; 1989 Apr; 35(5):564-70. PubMed ID: 2469809
[TBL] [Abstract][Full Text] [Related]
40. Unclassified hepatocellular adenoma with histological brown pigment deposition and serum PIVKA-II level elevation: a case report.
Hoshino K; Harimoto N; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Watanabe A; Kubo N; Araki K; Tomomasa R; Nobusawa S; Aishima S; Nakashima O; Shirabe K
Surg Case Rep; 2020 May; 6(1):94. PubMed ID: 32382834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
